Literature DB >> 6230541

The measurement of abnormal movement: methods developed for Huntington's disease.

S E Folstein, B Jensen, R J Leigh, M F Folstein.   

Abstract

Clinical and laboratory methods were developed to detect motor abnormalities in patients with Huntington Disease. For clinical evaluation a quantitated neurological examination was used which factor analyzed into 2 scales: a chorea scale (a measure of involuntary movement) and a motor impairment scale (a measure of abnormalities of voluntary movement). Mechanized methods of measuring involuntary movement (accelerometer) and voluntary movement (reaction time, tapping speed, and movement time) were also developed. The motor abnormalities detected on the clinical and mechanical tests were not specific to HD but were also present in persons at 50% risk for HD and in patients with a variety of neurological disorders. The mechanized tests may be useful for screening for motor disorders in the population: they are non-specific, portable and do not require the services of an experienced clinician.

Entities:  

Mesh:

Year:  1983        PMID: 6230541

Source DB:  PubMed          Journal:  Neurobehav Toxicol Teratol        ISSN: 0275-1380


  27 in total

1.  Episodic memory in dementia: Characteristics of new learning that differentiate Alzheimer's, Huntington's, and Parkinson's diseases.

Authors:  Eleni Aretouli; Jason Brandt
Journal:  Arch Clin Neuropsychol       Date:  2010-06-08       Impact factor: 2.813

2.  Brain metabolite alterations and cognitive dysfunction in early Huntington's disease.

Authors:  Paul G Unschuld; Richard A E Edden; Aaron Carass; Xinyang Liu; Megan Shanahan; Xin Wang; Kenichi Oishi; Jason Brandt; Susan S Bassett; Graham W Redgrave; Russell L Margolis; Peter C M van Zijl; Peter B Barker; Christopher A Ross
Journal:  Mov Disord       Date:  2012-05-30       Impact factor: 10.338

3.  Depression and suicidal ideation after predictive testing for Huntington's disease: a two-year follow-up study.

Authors:  Maria U Larsson; Mary A Luszcz; The-Hung Bui; Tarja-Brita Robins Wahlin
Journal:  J Genet Couns       Date:  2006-10       Impact factor: 2.537

4.  Measurement of caudate nucleus area--a more accurate measurement for Huntington's disease?

Authors:  J M Wardlaw; R J Sellar; L J Abernethy
Journal:  Neuroradiology       Date:  1991       Impact factor: 2.804

5.  Neuropsychological stability over two years in asymptomatic carriers of the Huntington's disease mutation.

Authors:  J R Campodonico; A M Codori; J Brandt
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-12       Impact factor: 10.154

6.  Impaired cortico-striatal functional connectivity in prodromal Huntington's Disease.

Authors:  Paul G Unschuld; Suresh E Joel; Xinyang Liu; Megan Shanahan; Russell L Margolis; Kevin M Biglan; Susan S Bassett; David J Schretlen; Graham W Redgrave; Peter C M van Zijl; James J Pekar; Christopher A Ross
Journal:  Neurosci Lett       Date:  2012-03-07       Impact factor: 3.046

7.  Depressive symptoms in prodromal Huntington's Disease correlate with Stroop-interference related functional connectivity in the ventromedial prefrontal cortex.

Authors:  Paul G Unschuld; Suresh E Joel; James J Pekar; Sarah A Reading; Kenichi Oishi; Julie McEntee; Megan Shanahan; Arnold Bakker; Russell L Margolis; Susan S Bassett; Adam Rosenblatt; Susumu Mori; Peter C van Zijl; Christopher A Ross; Graham W Redgrave
Journal:  Psychiatry Res       Date:  2012-09-11       Impact factor: 3.222

8.  Psychiatric disorders in preclinical Huntington's disease.

Authors:  Camille L Julien; Jennifer C Thompson; Sue Wild; Pamela Yardumian; Julie S Snowden; Gwen Turner; David Craufurd
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-12-18       Impact factor: 10.154

9.  Impaired prepulse inhibition of acoustic and tactile startle response in patients with Huntington's disease.

Authors:  N R Swerdlow; J Paulsen; D L Braff; N Butters; M A Geyer; M R Swenson
Journal:  J Neurol Neurosurg Psychiatry       Date:  1995-02       Impact factor: 10.154

10.  Dopamine D1 receptor number--a sensitive PET marker for early brain degeneration in Huntington's disease.

Authors:  G Sedvall; P Karlsson; A Lundin; M Anvret; T Suhara; C Halldin; L Farde
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1994       Impact factor: 5.270

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.